CD52 and breast carcinoma: CD52, also known as CAMPATH-1 antigen, is a glycoprotein which presents on the surface of lymphocytes.[74] Current research has mainly focused on the anti-tumor effects of the CD 52 antibody alemtuzumab in patients with lymphoma.[75] Together with CD3-gamma, -delta and -zeta, CD3-epsilon/CD3E forms the T cell receptor-CD3 complex, which plays a key role in antigen recognition and signal transduction.[76] Azadeh et al. found that a recombinant anti-CD3E nanobody effectively suppressed angiogenesis and tumor cell proliferation in a breast cancer mouse model.[59]